OBJECTIVE: To compare the efficacy and safety of three polyspecific antivenoms for bites by pit vipers. DESIGN: Randomised double blind comparative trial of three antivenoms. SETTING: Shell, Pastaza, southeastern Ecuador. PARTICIPANTS: 210 patients with incoagulable blood were recruited from 221 consecutive patients admitted with snake bite between January 1997 and December 2001. INTERVENTION: One of three antivenoms manufactured in Brazil, Colombia, and Ecuador, chosen for their preclinical potency against Ecuadorian venoms. MAIN OUTCOME MEASURES: Permanent restoration of blood coagulability after 6 and 24 hours. RESULTS: The snakes responsible for the bites were identified in 187 cases: 109 patients (58%) were bitten by Bothrops atrox, 68 (36%) by B bilineatus, and 10 (5%) by B taeniatus, B brazili, or Lachesis muta. Eighty seven patients (41%) receivedColombian antivenom, 82 (39%) received Brazilian antivenom, but only 41 (20%) received Ecuadorian antivenom because the supply was exhausted. Two patients died, and 10 developed local necrosis. All antivenoms achieved the primary end point of permanently restoring blood coagulability by 6 or 24 hours after the start of treatment in > 40% of patients. Colombian antivenom, however, was the most effective after initial doses of 20 ml (two vials), < 70 ml, and any initial dose at both 6 and 24 hours. An initial dose of 20 ml of Colombian antivenom permanently restored blood coagulability in 64% (46/72) of patients after 6 hours (P = 0.054 compared with the other two antivenoms) and an initial dose of < 70 ml was effective at 6 hours (65%, P = 0.045) and 24 hours (99%, P = 0.06). Early anaphylactoid reactions were common (53%, 73%, and 19%, respectively, for Brazilian, Colombian, and Ecuadorian antivenoms, P < 0.0001) but only three reactions were severe and none was fatal. CONCLUSIONS: All three antivenoms can be recommended for the treatment of snakebites in this region, though the reactogenicity of Brazilian and Colombian antivenoms is a cause for concern.
RCT Entities:
OBJECTIVE: To compare the efficacy and safety of three polyspecific antivenoms for bites by pit vipers. DESIGN: Randomised double blind comparative trial of three antivenoms. SETTING: Shell, Pastaza, southeastern Ecuador. PARTICIPANTS: 210 patients with incoagulable blood were recruited from 221 consecutive patients admitted with snake bite between January 1997 and December 2001. INTERVENTION: One of three antivenoms manufactured in Brazil, Colombia, and Ecuador, chosen for their preclinical potency against Ecuadorian venoms. MAIN OUTCOME MEASURES: Permanent restoration of blood coagulability after 6 and 24 hours. RESULTS: The snakes responsible for the bites were identified in 187 cases: 109 patients (58%) were bitten by Bothrops atrox, 68 (36%) by B bilineatus, and 10 (5%) by B taeniatus, B brazili, or Lachesis muta. Eighty seven patients (41%) received Colombian antivenom, 82 (39%) received Brazilian antivenom, but only 41 (20%) received Ecuadorian antivenom because the supply was exhausted. Two patients died, and 10 developed local necrosis. All antivenoms achieved the primary end point of permanently restoring blood coagulability by 6 or 24 hours after the start of treatment in > 40% of patients. Colombian antivenom, however, was the most effective after initial doses of 20 ml (two vials), < 70 ml, and any initial dose at both 6 and 24 hours. An initial dose of 20 ml of Colombian antivenom permanently restored blood coagulability in 64% (46/72) of patients after 6 hours (P = 0.054 compared with the other two antivenoms) and an initial dose of < 70 ml was effective at 6 hours (65%, P = 0.045) and 24 hours (99%, P = 0.06). Early anaphylactoid reactions were common (53%, 73%, and 19%, respectively, for Brazilian, Colombian, and Ecuadorian antivenoms, P < 0.0001) but only three reactions were severe and none was fatal. CONCLUSIONS: All three antivenoms can be recommended for the treatment of snakebites in this region, though the reactogenicity of Brazilian and Colombian antivenoms is a cause for concern.
Authors: C A Ariaratnam; L Sjöström; Z Raziek; S A Kularatne; R W Arachchi; M H Sheriff; R D Theakston; D A Warrell Journal: Trans R Soc Trop Med Hyg Date: 2001 Jan-Feb Impact factor: 2.184
Authors: D A Warrell; S Looareesuwan; R D Theakston; R E Phillips; P Chanthavanich; C Viravan; W Supanaranond; J Karbwang; M Ho; R A Hutton Journal: Am J Trop Med Hyg Date: 1986-11 Impact factor: 2.345
Authors: F O S França; K C Barbaro; H W Fan; J L C Cardoso; I S Sano-Martins; S C Tomy; M H Lopes; D A Warrell; R D G Theakston Journal: Trans R Soc Trop Med Hyg Date: 2003 May-Jun Impact factor: 2.184
Authors: Pedro Pereira de Oliveira Pardal; Suzana Medeiro Souza; Maria Rita de Cássia da Costa Monteiro; Hui Wen Fan; João Luiz Costa Cardoso; Francisco Oscar Siqueira França; Sandra Corrallo Tomy; Ida S Sano-Martins; Maria Cristina Cirillo de Sousa-e-Silva; Mônica Colombini; Nancy F Kodera; Ana Maria Moura-da-Silva; Diva Ferreira Cardoso; David Toledo Velarde; Aura S Kamiguti; Robert David Theakston; David A Warrell Journal: Trans R Soc Trop Med Hyg Date: 2004-01 Impact factor: 2.184
Authors: R E Phillips; R D Theakston; D A Warrell; Y Galigedara; D T Abeysekera; P Dissanayaka; R A Hutton; D J Aloysius Journal: Q J Med Date: 1988-09
Authors: Sanjib K Sharma; Patrick Bovier; Nilambar Jha; Emilie Alirol; Louis Loutan; François Chappuis Journal: Am J Trop Med Hyg Date: 2013-04-08 Impact factor: 2.345
Authors: Isa S Abubakar; Saidu B Abubakar; Abdulrazaq G Habib; Abdulsalam Nasidi; Nandul Durfa; Peter O Yusuf; Solomon Larnyang; John Garnvwa; Elijah Sokomba; Lateef Salako; R David G Theakston; Ed Juszczak; Nicola Alder; David A Warrell Journal: PLoS Negl Trop Dis Date: 2010-07-27
Authors: G K Isbister; S Jayamanne; F Mohamed; A H Dawson; K Maduwage; I Gawarammana; D G Lalloo; H J de Silva; F E Scorgie; L F Lincz; N A Buckley Journal: J Thromb Haemost Date: 2017-02-16 Impact factor: 5.824